Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 14, 10 Issues, 2014


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 26th of 59 in Chemistry, Medicinal
  • 99th of 197 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.61

Selected Approaches for Rational Drug Design and High Throughput Screening to Identify Anti-Cancer Molecules

Author(s): Michael Hedvat, Luni Emdad, Swadesh K. Das, Keetae Kim, Santanu Dasgupta, Shibu Thomas, Bin Hu, Shan Zhu, Rupesh Dash, Bridget A. Quinn, Regina A. Oyesanya, Timothy P. Kegelman, Upneet K. Sokhi, Siddik Sarkar and Eda Erdogan


Abstract

Structure-based modeling combined with rational drug design, and high throughput screening approaches offer significant potential for identifying and developing lead compounds with therapeutic potential. The present review focuses on these two approaches using explicit examples based on specific derivatives of Gossypol generated through rational design and applications of a cancer-specific-promoter derived from Progression Elevated Gene-3. The Gossypol derivative Sabutoclax (BI-97C1) displays potent anti-tumor activity against a diverse spectrum of human tumors. The model of the docked structure of Gossypol bound to Bcl-XL provided a virtual structure-activity-relationship where appropriate modifications were predicted on a rational basis. These structure-based studies led to the isolation of Sabutoclax, an optically pure isomer of Apogossypol displaying superior efficacy and reduced toxicity. These studies illustrate the power of combining structure-based modeling with rational design to predict appropriate derivatives of lead compounds to be empirically tested and evaluated for bioactivity. Another approach to cancer drug discovery utilizes a cancer-specific promoter as readouts of the transformed state. The promoter region of Progression Elevated Gene-3 is such a promoter with cancer-specific activity. The specificity of this promoter has been exploited as a means of constructing cancer terminator viruses that selectively kill cancer cells and as a systemic imaging modality that specifically visualizes in vivo cancer growth with no background from normal tissues. Screening of small molecule inhibitors that suppress the Progression Elevated Gene-3-promoter may provide relevant lead compounds for cancer therapy that can be combined with further structure-based approaches leading to the development of novel compounds for cancer therapy.


Purchase Online Rights and Permissions

Article Details

Volume: 13
First Page: 1
Last Page: 1
Page Count: 1
DOI: 10.2174/1871520611313030006
Advertisement


Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science